Phase I/II Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer
The purpose of this study is to study if the addition of the green tea extract, Polyphenon E, to Erlotinib is safe and if it has potential to improve outcomes in second line therapy for Advanced Stage IIIb/IV Non-small cell lung cancer.
100 Clinical Results associated with Polyphenon E International,Inc.
0 Patents (Medical) associated with Polyphenon E International,Inc.
100 Deals associated with Polyphenon E International,Inc.
100 Translational Medicine associated with Polyphenon E International,Inc.